Ollin Biosciences’ OLN324 bests Vabysmo in DME and wAMD head-to-head trial
Ollin Biosciences’ VEGF/Ang2 bispecific antibody has shown superiority over Roche’s Vabysmo (faricimab) in a head-to-head trial in diabetic macular oedema…
Ophthalmology
-
-
Belite eyes tinlarebant approval after late-stage Stargardt success
Belite Bio is seeking US approval of its lead ophthalmology asset, tinlarebant, in Stargardt disease 1 (STGD1) following the positive…
-
Sydnexis unveils more data for SYD-101 days after FDA refusal
Sydnexis has revealed further data of its paediatric progressive myopia (PPM) candidate, which met both the primary and secondary endpoints,…
-
FELIQS secures $9m for FLQ-101 to prevent retinopathy of prematurity
FELIQS has concluded a $9m Series A funding round, a significant step towards advancing the FLQ-101 clinical programme for preventing…
-
Viridian Therapeutics’ veligrotug shows durability in Phase III TED trial
Viridian Therapeutics’ veligrotug has shown one-year durability in a Phase III trial in patients with active thyroid eye disease (TED).…
-
VivaVision to advance non-steroidal therapy in Phase III following Phase II win
China-headquartered VivaVision Biotech is looking to advance its non-steroidal therapy, VVN461-CS-201 (VVN461), in a Phase III trial after the candidate…
-
Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial
Outlook Therapeutics’ second attempt to obtain US approval for its wet age-related macular degeneration (wet AMD) therapy, Lytenava (bevacizumab-vikg) has…
-
Glaukos eyes FDA approval for ocular therapy after Phase III win
Glaukos plans to file for US approval of its iLink corneal cross-linking therapy Epioxa (Epi-on) for treating keratoconus after the…
-
Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints
Viridian Therapeutics’s veligrotug has met all primary and secondary endpoints in a Phase III trial in active thyroid eye disease…
-
Boehringer and CDR-Life report data from geographic atrophy treatment trial
Boehringer Ingelheim and CDR-Life have reported positive outcomes from the Phase I clinical trial of BI 771716, a new treatment…
